XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables) | 9 Months Ended
--- | ---
Oct. 02, 2022
Earnings Per Share [Abstract] |
Schedule of Basic and Diluted Earning Per Share |
The following presents the detailed calculation of EPS:
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021
EPS Numerator––Basic |  |  |  |  |  |  |  |
Income from continuing operations attributable to Pfizer Inc. common shareholders |  | $ | 8,630 |  |  | $ | 8,159 |  |  | $ | 26,373 |  |  | $ | 18,834 |
Discontinued operations––net of tax |  | (21) |  |  | (13) |  |  | 4 |  |  | (248) |
Net income attributable to Pfizer Inc. common shareholders |  | $ | 8,608 |  |  | $ | 8,146 |  |  | $ | 26,378 |  |  | $ | 18,586 |
EPS Numerator––Diluted |  |  |  |  |  |  |  |
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions |  | $ | 8,630 |  |  | $ | 8,159 |  |  | $ | 26,373 |  |  | $ | 18,834 |
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions |  | (21) |  |  | (13) |  |  | 4 |  |  | (248) |
Net income attributable to Pfizer Inc. common shareholders and assumed conversions |  | $ | 8,608 |  |  | $ | 8,146 |  |  | $ | 26,378 |  |  | $ | 18,586 |
EPS Denominator |  |  |  |  |  |  |  |
Weighted-average number of common shares outstanding––Basic |  | 5,607 |  |  | 5,609 |  |  | 5,606 |  |  | 5,597 |
Common-share equivalents: stock options and stock issuable under employee compensation plans |  | 111 |  |  | 116 |  |  | 124 |  |  | 91 |
Weighted-average number of common shares outstanding––Diluted |  | 5,718 |  |  | 5,725 |  |  | 5,729 |  |  | 5,688 |
Anti-dilutive common stock equivalents(a) |  | 3 |  |  | — |  |  | 1 |  |  | 3 |
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration